Retatrutide Dosage Conversion: Theoretical Calculations

Retatrutide is an investigational medication currently in Phase 3 clinical trials conducted by Eli Lilly. It has not received FDA approval and is not available through any pharmacy, compounding facility, or commercial source. The dosage conversion information in this guide is provided for educational purposes only -- to illustrate how the standard GLP-1 vial calculation would apply to retatrutide if and when it becomes available.

Do not attempt to obtain, compound, or self-administer retatrutide based on this or any other calculation guide. Any product marketed as retatrutide outside of a clinical trial is unregulated and potentially dangerous.

The same universal formula used for semaglutide and tirzepatide would apply to retatrutide if it were available in compounded vial form:

units = (dose in mg / concentration in mg/mL) x 100

This formula works for any injectable medication administered from a vial using a U-100 insulin syringe, regardless of the specific drug. The inputs are the prescribed dose in milligrams and the vial concentration in mg/mL.

In clinical trials, retatrutide is administered at doses of 1, 2, 4, 8, and 12 mg weekly. If a hypothetical compounded vial were available at, say, 10 mg/mL, the conversion for a 12 mg dose would be:

units = (12 / 10) x 100 = 120 units (1.2 mL)

That volume would exceed a standard 1 mL syringe, which is why higher concentrations would likely be needed for the upper dose range.

Based on the clinical trial dose range (1-12 mg), compounded retatrutide vials would likely need concentrations in the range of 10-40 mg/mL to keep injection volumes practical. Here is how different theoretical concentrations would work for the most common trial doses:

At 10 mg/mL: 4 mg = 40 units (0.4 mL) 8 mg = 80 units (0.8 mL) 12 mg = 120 units (1.2 mL -- too large for most syringes)

At 20 mg/mL: 4 mg = 20 units (0.2 mL) 8 mg = 40 units (0.4 mL) 12 mg = 60 units (0.6 mL)

At 30 mg/mL: 4 mg = 13.3 units (0.13 mL) 8 mg = 26.7 units (0.27 mL) 12 mg = 40 units (0.4 mL)

A concentration of 20-30 mg/mL would be optimal for most doses, similar to the range used for compounded tirzepatide. However, these are purely theoretical since no compounded retatrutide product exists.

Understanding dosage conversion for retatrutide is relevant for healthcare professionals monitoring clinical trials, researchers studying GLP-1-class pharmacology, and compounding pharmacists preparing for potential future formulations. The standard conversion formula is a fundamental concept in injectable medication dosing and applies universally.

For patients currently seeking weight loss treatment, the same formula is already in use every day for compounded semaglutide and tirzepatide. If you are prescribed either of these medications from a compounded vial, the calculation process is identical: verify your vial concentration, apply the formula, and draw the correct number of units on a U-100 insulin syringe. Our dosage calculators automate this process for currently available medications.

The key takeaway is that dosage conversion is a transferable skill. If you learn to calculate syringe units for semaglutide or tirzepatide today, you will already understand the process if retatrutide becomes available in compounded form in the future. The math does not change -- only the specific numbers do.